Sudden death in a traveler following halofantrine administration--Togo, 2000.
On July 17, 2000, a previously healthy 22-year-old U.S. student collapsed and died suddenly while leading a teenage exchange group in West Africa. This report summarizes the results of the investigations of this incident, which implicate use of halofantrine for treatment of malaria as the cause of death. Travelers should be warned that halofantrine treatment may be dangerous in persons with cardiac abnormalities or in those taking mefloquine for malaria prophylaxis.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000962:Antimalarials / Q000009:adverse effects*; D006332:Cardiomegaly / Q000150:complications*; D003645:Death, Sudden / Q000209:etiology*; D004347:Drug Interactions; D004917:Erythromycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015767:Mefloquine / Q000627:therapeutic use; D010616:Phenanthrenes / Q000009:adverse effects*; D014037:Togo; D014195:Travel
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D010616:Phenanthrenes; D004917:Erythromycin; D015767:Mefloquine